The objective of this study is to explore the role of fosmidomycin and piperaquine as non-artemisinin-based combination therapy for acute uncomplicated Plasmodium falciparum when administered over three days. Together, fosmidomycin and piperaquine fulfil the WHO criteria for combination therapy by meeting the three key parameters of having different modes of action and different biochemical targets while exhibiting independent blood schizonticidal activity. Like the artemisinins, fosmidomycin is fast-acting, has an excellent safety record and is active against existing drug-resistant parasites. Piperaquine has a long half life protecting fosmidomycin as a much shorter lived molecule against selection of resistant parasites and will provide post-treatment prophylaxis.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Per protocol, PCR-corrected cure rate on Day 28
Six-hourly asexual counts until negative on three successive occasions. Weekly smears on days 7, 14, 21 and 28
Time frame: 28 days
Per protocol, PCR-corrected cure rates on Day 7 and Day 63
Weekly smears on days 35 +/- 3 days, 42 +/- 3 days and 63 +/- 3 days
Time frame: 63 days
Derived parasite reduction ratio at 48 hours
Six-hourly asexual counts until negative on three successive occasions
Time frame: 2 days
Parasite clearance time
Six-hourly asexual counts until negative on three successive occasions
Time frame: 96 hours
Fever clearance time
Six hourly temperature recordings until normal on three successisve occasions
Time frame: 96 hours
Proportion of subjects with gametocytes on Day 7
Smear on Day 7
Time frame: 7 days
Adverse event recording
Recording of vital signs and ECG monitoring Recording of incidence, severity, drug-relatedness and seriousness of AEs and laboratory abnormalites
Time frame: 28 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.